| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30082247 | HIV | ENSG00000104267.10 | protein_coding | CA2 | No | No | 760 | P00918 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CA2 |
|---|---|
| DrugBank ID | DB00774 |
| Drug Name | Hydroflumethiazide |
| Target ID | BE0000322 |
| UniProt ID | P00918 |
| Regulation Type | inhibitor |
| PubMed IDs | 2226620; 19119014 |
| Citations | Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8.@@Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. |
| Groups | Approved; Investigational; Withdrawn |
| Direct Classification | 1,2,4-benzothiadiazine-1,1-dioxides |
| SMILES | NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F |
| Pathways | Hydroflumethiazide Action Pathway |
| PharmGKB | PA164752557 |
| ChEMBL | CHEMBL1763 |
